DTPA prodrugs, compositions thereof, and methods of using the same

US9546129B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9546129-B2
Application numberUS-201514721552-A
CountryUS
Kind codeB2
Filing dateMay 26, 2015
Priority dateNov 26, 2012
Publication dateJan 17, 2017
Grant dateJan 17, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to trisodium diethylenetriamine pentaacetic acid (DTPA) prodrugs, such as, for example, DTPA di-ethyl esters. The invention further relates to compositions comprising DTPA prodrugs and methods of using the same.

First claim

Opening claim text (preview).

That which is claimed is: 1. A polymorph of 6,9-bis(carboxymethyl)-3-(2-ethoxy-2-oxoethyl)-11-oxo-12-oxa-3,6,9-triazatetradecan-1-oic acid characterized by a powder x-ray diffraction pattern substantially the same as that shown in FIG. 6D and/or a powder x-ray diffraction pattern having peaks at about 8.1, 12.0, 13.8, 15.4, 16.0, 16.6, 18.3, 19.3, 21.4, 22.1, 24.0, 26.5, and 29.2±0.2 degrees 2 theta, wherein the polymorph has a melting point in a range from 133° C. to 141° C. 2. The polymorph of claim 1 , wherein the melting point is measured using differential scanning calorimetry over a range of about 25° C. to about 320° C. with a heating rate of about 10.00° C./min. 3. A process of preparing the polymorph of 6,9-bis(carboxymethyl)-3-(2-ethoxy-2-oxoethyl)-11-oxo-12-oxa-3,6,9-triazatetradecan-1-oic acid of claim 1 , comprising (a) combining DTPA bis-anhydride and absolute ethanol to form a reaction mixture; (b) heating the reaction mixture to reflux while stirring for about 1.5 hours; (c) filtering the reaction mixture to form a filtrate; (d) cooling the filtrate to a temperature below about 20° C. to form a precipitate of a polymorph of 6,9-bis(carboxymethyl)-3-(2-ethoxy-2-oxoethyl)-11-oxo-12-oxa-3,6,9-triazatetradecan-1-oic acid; (e) filtering the filtrate to obtain the precipitate; (f) optionally washing the precipitate with cold ethanol; (g) optionally washing the precipitate with methyl tert-butyl ether to form a filter cake; (h) optionally mixing the filter cake with ethanol to form a second slurry; (i) optionally heating the second slurry to a temperature of about 70° C.; (j) optionally filtering the second slurry to form a second filtrate; (k) optionally cooling the second filtrate to a temperature below about 20° C. to form a second precipitate; (l) optionally filtering the second filtrate to obtain the second precipitate; and (m) optionally drying the precipitate, thereby obtaining the polymorph. 4. A method of treating a subject to remove a radioactive element from the subject comprising: administering a therapeutically effective amount of the polymorph of claim 1 to a subject, thereby removing the radioactive element from the subject. 5. The method of claim 4 , wherein the administering step delivers to the subject from about 1 mg to about 2,000 mg of the polymorph per kilogram of the subject's total body weight. 6. The method of claim 4 , wherein the administering step is prior to the subject's exposure to a radioactive element. 7. The method of claim 6 , wherein the administering step is carried out to prevent incorporation of a radioactive element into the subject's tissues, organs, bones, or any combination thereof. 8. The method of claim 4 , wherein the administering step is after the subject's exposure to a radioactive element. 9. The method of claim 4 , wherein the radioactive element comprises an isotope of plutonium (Pu), americium (Am), curium (Cm), or any combination thereof. 10. The method of claim 4 , wherein the subject is a mammal.

Assignees

Inventors

Classifications

  • Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton · CPC title

  • C07C229/26Primary

    having more than one amino group bound to the carbon skeleton, e.g. lysine · CPC title

  • Crystalline forms, e.g. polymorphs · CPC title

  • Two oxygen atoms, in positions 3 and 5 · CPC title

  • Polycarboxylic acids · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9546129B2 cover?
The present invention relates to trisodium diethylenetriamine pentaacetic acid (DTPA) prodrugs, such as, for example, DTPA di-ethyl esters. The invention further relates to compositions comprising DTPA prodrugs and methods of using the same.
Who is the assignee on this patent?
Univ North Carolina Chapel Hill
What technology area does this patent fall under?
Primary CPC classification C07C229/26. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).